Company News: Page (1) of 1 - 10/18/17

Merck to Present New Data on MS Portfolio: Rebif, Mavenclad, and Evobrutinib at ECTRIMS 2017

- Important safety and immune cell analyses further characterize the selective immune reconstitution approach of Mavenclad- Continued innovation with Rebif includes analysis of NEDA and use of MAGNIMS...

October 18, 2017 -- !-- AddToAny BEGIN -->
This article is no longer available,but here are some related topics.

Page: 1
Related Keywords:Family,Adults,Family,Computers/Home Office,Communications,Digital Toys,Tablets,Networks,Smart Phone,tablet,Tablet,Sales,Marketing,Shipping & Receiving,Sales & Marketing,Database,Internet,Business Issues,Other,Administration,Management,Sales,Sales,Pro AV,Management,

Source:PR Newswire. All Rights Reserved

Our Privacy Policy --- @ Copyright, 2015 Digital Media Online, All Rights Reserved